ArticleGeroScience2024
Plasma neurofilament light chain in relation to 10-year change in cognition and neuroimaging markers: a population-based study.
Article in GeroScience, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 19 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
19 citing papers in PubMed, 1 synthesis or guideline pooled it, 22 citations in OpenAlex.
- Plasma Biomarkers for Alzheimer's Disease Across the Continuum: A Systematic Review of SIMOA-Based Studies.Cellular and molecular neurobiology · 2026Pooled it
- Exploring blood-based biomarkers in late-life depression: Correlates of psychotherapeutic treatment outcomes.European psychiatry : the journal of the Association of European Psychiatrists · 2026Trial
- Blood Biomarkers of Alzheimer Disease and Rates of Global and Domain-Specific Cognitive Decline.JAMA network open · 2026Article
- Joint trajectories of brain atrophy, white matter hyperintensities and cognition quantify brain maintenance.Nature communications · 2026Article
- The association between neurofilament light chain and cognitive function: a UK Biobank cohort study.Journal of neurology · 2026Article
- Potential diagnostic markers in Alzheimer's disease: current perspectives and future directions.Neurodegenerative disease management · 2026Review
- AD-related plasma biomarkers in centenarians: links to cognition and neuropathology.Alzheimer's & dementia : the journal of the Alzheimer's Association · 2025Article
- Path integration impairments reveal early cognitive changes in subjective cognitive decline.Science advances · 2025Article
- Path integration impairments reveal early cognitive changes in Subjective Cognitive Decline.bioRxiv : the preprint server for biology · 2025Article
- Article
- Comparison of Simoa and Lumipulse Neurofilament Light Chain Measurements in Alzheimer's Cerebrospinal Fluid: Preliminary Findings.Brain sciences · 2025Article
- Expression patterns of blood-based biomarkers of neurodegeneration and inflammation across adulthood in rhesus macaques.Experimental gerontology · 2025Article
- Association of hemoglobin with plasma neurofilament light and white matter hyperintensities in Alzheimer's disease continuum.Heliyon · 2024Article
- Joint effect of testosterone and neurofilament light chain on cognitive decline in men: The Shanghai Aging Study.Alzheimer's & dementia : the journal of the Alzheimer's Association · 2024Article
- Potential role of blood pressure variability and plasma neurofilament light in the mechanism of comorbidity between Alzheimer's disease and cerebral small vessel disease.Alzheimer's & dementia : the journal of the Alzheimer's Association · 2024Article
- Article
- Mapping neurodegeneration across the Huntington's disease spectrum: a five-year longitudinal analysis of plasma neurofilament light.EBioMedicine · 2024Article
- Associations of plasma neurofilament light chain with cognition and neuroimaging measures in community-dwelling early old age men.Alzheimer's research & therapy · 2024Article
- Blood Biomarkers of Alzheimer's Disease and Cognition: A Literature Review.Biomolecules · 2024Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 2 institutions in 2 countries.
Funding
Abstract
Neurofilament light chain (NfL) is a promising biomarker for risk stratification and disease monitoring of dementia, but its utility in the preclinical disease stage remains uncertain. We determined the association of plasma NfL with (change in) neuroimaging markers and cognition in the population-based Rotterdam Study, using linear and logistic regression and mixed-effects models. Plasma NfL levels were measured using the Simoa NF-light™ assay in 4705 dementia-free participants (mean age 71.9 years, 57% women), who underwent cognitive assessment and brain MRI with repeated assessments over a 10-year follow-up period. Higher plasma NfL was associated with worse cognitive performance at baseline (g-factor: β = - 0.12 (- 0.15; - 0.09), p < 0.001), and accelerated cognitive decline during follow-up on the Stroop color naming task (β = 0.04 (0.02; 0.06), p < 0.001), with a smaller trend for decline in global cognition (g-factor β = - 0.02 (- 0.04; 0.00), p = 0.044). In the subset of 975 participants with brain MRI, higher NfL was associated with poorer baseline white matter integrity (e.g., global mean diffusivity: β = 0.12 (0.06; 0.19), p < 0.001), with similar trends for volume of white matter hyperintensities (β = 0.09 (0.02; 0.16), p = 0.011) and presence of lacunes (OR = 1.55 (1.13; 2.14), p = 0.007). Plasma NfL was not associated with volumes or thickness of the total gray matter, hippocampus, or Alzheimer signature regions. In conclusion, higher plasma NfL levels are associated with cognitive decline and larger burden of primarily white matter pathology in the general population.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.